51
|
Ronchi S, Vischioni B, Bonora M, Vitolo V, Fiore M, Iannalfi A, Barcellini A, Molinelli S, Russo S, Maestri D, Ciocca M, Preda L, Valvo F. PO-0850: Proton Beam Reirradiation In Head And Neck Patients at CNAO: preliminary results. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00867-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
52
|
Esposito M, Ghirelli A, Pini S, Russo S, Alpi P, Barca R, Fondelli S, Leonulli BG, Paoletti L, Rossi F, Bastiani P. PD-0182: Elastically deformed planning CT improves in vivo dosimetry results for Head and Neck treatments. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00206-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
53
|
Gnerucci A, Russo S, Esposito M, Ghirelli A, Pini S, Rossi F, Paoletti L, Barca R, Fondelli S, Alpi P, Grilli B, Bastiani P. PO-1621: Surface Guided Radiotherapy for locoregional DIBH treatment: Intrafraction motion evaluation. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01639-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
54
|
Russo S, Gala GD, Hernandez V, Esposito M, Pini S, Ghirelli A, Saez J, Ghafour H, Zatelli G. PD-0183: Does the detector resolution influence correlations between complexity metrics and VMAT QA results? Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00207-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
55
|
Marvaso G, Gugliandolo S, Comi S, Pepa M, Russo S, Vischioni B, Valvo F, Giandini T, Avuzzi B, Valdagni R, Ciardo D, Jereczek-Fossa B, Cattani F, Orecchia R. PO-1748: Carbon-ion boost followed by photon IMRT for PCa: dosimetric and geometric evaluations, AIRCIG. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01766-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
56
|
Segovia M, Russo S, Girotti MR, Rabinovich GA, Hill M. Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers. Clin Exp Immunol 2020; 200:155-162. [PMID: 32297328 DOI: 10.1111/cei.13433] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Revised: 03/17/2020] [Accepted: 03/19/2020] [Indexed: 12/12/2022] Open
Abstract
Immune checkpoint blockers improve the overall survival of a limited number of patients among different cancers. Identifying pathways that influence the immunological and clinical response to treatment is critical to improve the therapeutic efficacy and predict clinical responses. Recently, a key role has been assigned to innate immune mechanisms in checkpoint blockade-driven anti-tumor responses. However, inflammatory pathways can both improve and impair anti-tumor immunity. In this review, we discuss how different inflammatory pathways, particularly inflammasome activation, can influence the clinical outcome of immune checkpoint blockers. Inflammasome activation may reinforce anti-tumor immunity by boosting CD8+ T cell priming as well as by enhancing T helper type 17 (Th17) responses. In particular, we focus on the modulation of the cation channel transmembrane protein 176B (TMEM176B) and the ectonucleotidase CD39 as potential targets to unleash inflammasome activation leading to reinforced anti-tumor immunity and improved efficacy of immune checkpoint blockers. Future studies should be aimed at investigating the mechanisms and cell subsets involved in inflammasome-driven anti-tumor responses.
Collapse
|
57
|
Bianchini G, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Russo S, Ciruelos E, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Smart C, Valagussa P, Viale G, Gianni L. LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2241] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
58
|
Giavarra M, Bertoli E, Buoro V, Zara D, Targato G, Palmero L, Vitale M, Pelizzari G, Basile D, Gerratana L, Bonotto M, Andreetta C, Cinausero M, Pascoletti G, Poletto E, Russo S, Puglisi F, Fasola G, Mansutti M, Minisini A. Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program? Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
59
|
Mirandola A, Magro G, Maestri D, Mairani A, Mastella E, Molinelli S, Russo S, Vai A, Ciocca M. Determination of ion recombination and polarity effect correction factors for a plane-parallel ionization Bragg peak chamber under proton and carbon ion pencil beams. Phys Med Biol 2019; 64:095010. [PMID: 30844771 DOI: 10.1088/1361-6560/ab0db4] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Within the dosimetric characterization of particle beams, laterally-integrated depth-dose-distributions (IDDs) are measured and provided to the treatment planning system (TPS) for beam modeling or used as a benchmark for Monte Carlo (MC) simulations. The purpose of this work is the evaluation, in terms of ion recombination and polarity effect, of the dosimetric correction to be applied to proton and carbon ion curves as a function of linear energy transfer (LET). LET was calculated with a MC code for selected IDDs. Several regions of Bragg peak (BP) curve were investigated. The charge was measured with the plane-parallel BP-ionization chamber mounted in the Peakfinder as a field detector, by delivering a fixed number of particles at the maximum flux. The dose rate dependence was evaluated for different flux levels. The chamber was connected to an electrometer and exposed to un-scanned pencil beams. For each measurement the chamber was supplied with {±400, +200, +100} V. Recombination and polarity correction factors were then calculated as a function of depth and LET in water. Three energies representative of the clinical range were investigated for both particle types. The corrected IDDs (IDD k s) were then compared against MC. Recombination correction factors were LET and energy dependent, ranging from 1.000 to 1.040 (±0.5%) for carbon ions, while nearly negligible for protons. Moreover, no corrections need to be applied due to polarity effect being <0.5% along the whole IDDs for both particle types. IDD k s showed a better agreement than uncorrected curves when compared to MC, with a reduction of the mean absolute variation from 1.2% to 0.9%. The aforementioned correction factors were estimated and applied along the IDDs, showing an improved agreement against MC. Results confirmed that corrections are not negligible for carbon ions, particularly around the BP region.
Collapse
|
60
|
Vai A, Meschini G, Molinelli S, Paganelli C, Maestri D, Magro G, Mastella E, Mairani A, Mirandola A, Russo S, Preda L, Viselener G, Barcellini A, Vitolo V, Mancin A, Fontana G, Baroni G, Ciocca M. EP-1968 Respiratory-gated carbon-ion beam treatments of abdominal targets: clinical introduction of 4DMRI. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32388-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
61
|
Esposito M, Ghirelli A, Pini S, Russo S, Zatelli G, Alpi P, Barca R, Leonulli BG, Paoletti L, Rossi F, Bastiani P. EP-1755 Implementation of EPID in vivo dosimetry for SBRT: setting tolerance levels for routine clinical use. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32175-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
62
|
Vai A, Maestri D, Magro G, Mairani A, Mastella E, Mirandola A, Molinelli S, Russo S, Togno M, La Civita S, Ciocca M. PO-0894 Characterization of a multilayer ionization chamber for relative depth-dose curves in particle beams. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31314-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
63
|
Maestri D, Mirandola A, Magro G, Mairani A, Mastella E, Molinelli S, Russo S, Vai A, Ciocca M. EP-1756 Ion recombination and polarity correction for a plane-parallel ionization chamber in hadrontherapy. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32176-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
64
|
Barcellini A, Vitolo V, Fiore M, Iannalfi A, Vischioni B, Fossati P, Ronchi S, Bonora M, D'Ippolito E, Petrucci R, Facoetti A, Mirandola A, Vai A, Molinelli S, Mastella E, Russo S, Viselner G, Preda L, Ciocca M, Valvo F, Orecchia R. EP-1496 Feasibility of carbon ion radiotherapy for the melanoma of the lower genital tract. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31916-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
65
|
Falco M, Fusella M, Fiandra C, Clemente S, Garibaldi C, Casati M, Giglioli F, Gallio E, Malatesta T, Delana A, Marino C, Soriani A, Linsalata S, Bagalà P, Benecchi G, Consorti R, Casale M, Reggiori G, Villaggi E, Russo S, Mancosu P. EP-1779 Impact of calculation grid resolution and CT slice thickness on TPS calculated small fields OF. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32199-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
66
|
Esposito M, Ghirelli A, Pini S, Russo S, Zatelli G, Alpi P, Barca R, Fondelli S, Grilli Leonulli B, Paoletti L, Rossi F, Bastani P. EP-1847 Automatic optimization of Head and Neck treatments with multicriteria radiobiological cost functions. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32267-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
67
|
Savini A, Cilla S, Esposito M, Moretti E, Villaggi E, Russo S, Stasi M, Mancosu P. EP-2095 SBRT of prostate with integrated boost of Dominant Lesion. A crowd-knowledge based planning study. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32515-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
68
|
Iannalfi A, D’Ippolito E, Vitolo V, Vischioni B, Fiore M, Bonora M, Ronchi S, Barcellini A, Petrucci R, Molinelli S, Mirandola A, Russo S, Facoetti A, Vai A, Mastella E, Viselner G, Magro G, Ciocca M, Preda L, Valvo F, Orecchia R. PO-0716 Skull-base chordoma treated with proton and carbon ion radiotherapy : CNAO clinical experience. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31136-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
69
|
Corrado B, Albano M, Caprio M, Di Luise C, Sansone M, Servodidio V, Russo S, Vallone G, Vola E, Servodio Iammarrone C. Usefulness of point shear wave elastography to assess the effects of extracorporeal shockwaves on spastic muscles in children with cerebral palsy: an uncontrolled experimental study. ACTA ACUST UNITED AC 2019. [DOI: 10.32098/mltj.01.2019.04] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
70
|
Giorgio C, Incerti M, Pala D, Russo S, Chiodelli P, Rusnati M, Cantoni A, Di Lecce R, Barocelli E, Bertoni S, Ravassard P, Manenti F, Piemonti L, Ferlenghi F, Lodola A, Tognolini M. Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice. Pharmacol Res 2019; 141:319-330. [DOI: 10.1016/j.phrs.2019.01.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 11/05/2018] [Accepted: 01/04/2019] [Indexed: 01/22/2023]
|
71
|
Russo S, Baumann SL, Velasco-Whetsell M, Roy C. A Comparison of Two Case Studies Using the Roy Adaptation Model: Parents of Opioid-Dependent Adults and Bariatric Surgery. Nurs Sci Q 2019; 32:61-67. [PMID: 30798751 DOI: 10.1177/0894318418807943] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The authors in this paper demonstrate the utility and versatility of the Roy Adaptation Model (RAM) as applied to two contemporary case studies. The first case uses the RAM model to gain understanding and guide nursing practice to assist the parents of a young adult with an opioid use disorder and depression, and the second case involves using the RAM model to help a woman who recently had bariatric surgery cope and adapt postoperatively in a way that helps her maximize the benefits of having had that procedure. The authors discuss how the RAM provides a holistic approach that can be used to provide high-quality, comprehensive nursing.
Collapse
|
72
|
De Placido S, De Laurentiis M, Bruzzese D, Bernardo A, Baldini EE, Montesarchio V, Fabi A, Gamucci T, De Placido P, Russo S, Lauria R, De Santo I, De Angelis C, Del Mastro L, Giuliano M, Arpino G. Abstract P6-21-13: A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxel. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-21-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: At present, there is no standard second-line chemotherapy-based treatment in patients with HER2-negative MBC. Continued VEGF inhibition with bevacizumab is a new potential option in patients progressing to first line bevacizumab and chemotherapy. Eribulin is a non-taxane microtubule dynamics inhibitor, with a unique mechanism of action and suggested beneficial effects on tumor microenvironment and neoangiogenesis. This study evaluated efficacy and safety of eribulin plus bevacizumab as a novel second-line chemotherapy scheme, in patients progressing after first line paclitaxel and bevacizumab.
Methods: This is a multicenter, single-arm, Simon's two-stage, Phase II study. Patients with HER2-negative MBC progressing to paclitaxel and bevacizumab received eribulin (1.23 mg/m2 intravenously on Days 1 and 8 of every 21-day cycle) plus bevacizumab (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks intravenously), as second-line chemotherapy. The primary endpoint was the overall response rate (ORR), considered as sum of partial (PR) and complete response (CR), basing on the best overall response. The present safety and efficacy analyses, as planned per study design, refer to six cycles of treatment (18 weeks).
Results: Among the 61 patients enrolled in the study, 55 (90,2% ) were evaluable for efficacy. ORR (PR/CR) was 9.1% [95% confidence intervals (C.I.) 3.0 to 19.9]; stable disease (SD) rate was 63.6% [95% C.I. 49.6 to 76.2]; clinical benefit rate (CR/PR/SD) at 24 weeks was 35% [95% C.I. 22.0 to 49.1]. The median progression free survival was 6.3 months [95% C.I. 4.1 to 7.8 months]. Drugs-related adverse events (AEs) were: 49.5% related to eribulin, 7.7% related to bevacizumab, and 11.8% related to both the study drugs. The most common AEs were fatigue (9.9% of all AEs), paresthesia (6.5% of all AEs) and neutropenia (6.2% of all AEs). Quality of life was well preserved among the majority of patients.
Conclusions: The results of our trial suggest that continuing bevacizumab in combination with eribulin, beyond first line treatment with bevacizumab and paclitaxel, offers a reasonable therapeutic option for patients with HER2-negative MBC, without detrimentally affecting quality of life.
Citation Format: De Placido S, De Laurentiis M, Bruzzese D, Bernardo A, Baldini EE, Montesarchio V, Fabi A, Gamucci T, De Placido P, Russo S, Lauria R, De Santo I, De Angelis C, Del Mastro L, Giuliano M, Arpino G. A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxel [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-21-13.
Collapse
|
73
|
Peimyoo N, Barnes MD, Mehew JD, De Sanctis A, Amit I, Escolar J, Anastasiou K, Rooney AP, Haigh SJ, Russo S, Craciun MF, Withers F. Laser-writable high-k dielectric for van der Waals nanoelectronics. SCIENCE ADVANCES 2019; 5:eaau0906. [PMID: 30746444 PMCID: PMC6357741 DOI: 10.1126/sciadv.aau0906] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Accepted: 12/07/2018] [Indexed: 05/14/2023]
Abstract
Similar to silicon-based semiconductor devices, van der Waals heterostructures require integration with high-k oxides. Here, we demonstrate a method to embed and pattern a multifunctional few-nanometer-thick high-k oxide within various van der Waals devices without degrading the properties of the neighboring two-dimensional materials. This transformation allows for the creation of several fundamental nanoelectronic and optoelectronic devices, including flexible Schottky barrier field-effect transistors, dual-gated graphene transistors, and vertical light-emitting/detecting tunneling transistors. Furthermore, upon dielectric breakdown, electrically conductive filaments are formed. This filamentation process can be used to electrically contact encapsulated conductive materials. Careful control of the filamentation process also allows for reversible switching memories. This nondestructive embedding of a high-k oxide within complex van der Waals heterostructures could play an important role in future flexible multifunctional van der Waals devices.
Collapse
|
74
|
Russo S, Esposito M, Hernandez V, Saez J, Rossi F, Paoletti L, Bastiani P, Tomatis S, Mancosu P. 3. Is DIBH VMAT in left breast related to lower plan complexity than Free Breathing? A multicenter experience. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
75
|
Lastrucci A, Barucci A, Pini S, Russo S, Alpi P, Barca R, Coppola M, Fondelli S, Paoletti L, Rossi F, Bastiani P, Esposito M. 159. Evaluation of a user-guided deformable registration workflow for multi-modal (CT-MRI) prostate imaging. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
76
|
Villaggi E, Esposito M, Hernández V, Sáez J, Marino C, Bonanno E, Bruschi A, Borzì G, Carbonini C, Consorti R, Fedele D, Moretti E, Nardiello B, Russo S, Vaccara E, Stasi M, Mancosu P. 31. Impact of DVH sharing and experience level in a multicenter SBRT prostate planning study. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
77
|
Savini A, Fusella M, Esposito M, Ardu V, Benecchi G, Bergantin A, Borzi G, Bresciani S, Cagni E, Carbonini C, Casati M, Clemente S, Consorti R, Cora S, DeMartin E, ElGawhary R, Falco M, Fedele D, Fiandra C, Frassanito M, Garibaldi C, Gasperi G, Giglioli F, Guidi G, Ielo I, Landoni V, Magi S, Malatesta T, Marino C, Masi L, Moretti E, Naccarato S, Nardiello B, Nigro R, Pastore G, Presello M, Ravaglia V, Russo S, Strigari L, Strolin S, Talamonti C, Vaiano A, Vigorito S, Villaggi E, Stasi M, Mancosu P. 161. A crowd-knowledge-based analysis of DVHs in SBRT: First steps towards a national virtual audit. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
78
|
Falco M, Clemente S, Fiandra C, Agostinelli S, Bagalà P, Benecchi G, Borzì G, Bresciani S, Broggi S, Carbonini C, Casale M, Casati M, Consorti R, Corletto D, Delana A, Esposito M, Fusella M, Garibaldi C, Iervolino C, Linsalata S, Malatesta T, Manco L, Marino C, Menghi E, Moretti E, Nardiello B, Reggiori G, Romagnoli F, Soriani A, Villaggi E, Russo S, Mancosu P. 141. A preliminary study to evaluate the impact of calculation grid resolution and CT slice thickness on TPS calculated small fields OF. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
79
|
Pini S, Russo S, Esposito M, Paoletti L, Alpi P, Barca R, Coppola M, Fondelli S, Grilli B, Rossi F, Bastiani P. 130. Inter-fraction variability of respiratory-induced tumour motion in lung SBRT: 4D-CBCT. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.141] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
80
|
Marino C, Carbonini C, Veronese I, Agostinelli S, Aimonetto S, Bagalà P, Barbiero S, Benecchi G, Borzi G, Bresciani S, Broggi S, Cagni E, Casale M, Cilla S, Clemente S, Consorti R, Corletto D, Delana A, Esposito M, Falco M, Fedele D, Fusella M, Garibaldi C, Gasperi C, Giglioli F, Giancaterino S, Iervolino C, Infusino E, Mameli A, Manco L, Masi L, Menghi E, Moretti E, Nardiello B, Paladini L, Panizza D, Pastore G, Radice A, Redaelli I, Rosica F, Russo S, Saiani F, Savini A, Siragusa C, Strigari L, Talamonti C, Vaccara E, Villaggi E, Zucchetti C, Stasi M, Mancosu P. 40. Design of a national survey to assess the technology applied to SBRT. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
81
|
Pelizzari G, Gerratana L, Basile D, Zago S, Vitale M, Bartoletti M, Lisanti C, Fanotto V, Corvaja C, Bortot L, Liguori A, Cinausero M, Russo S, Andreetta C, Bonotto M, Mansutti M, Minisini A, Curcio F, Fasola G, Puglisi F. A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.292] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
82
|
Iannalfi A, D’Ippolito E, Vitolo V, Vischioni B, Fiore M, Bonora M, Ronchi S, Caivano D, Barcellini A, Mirandola A, Molinelli S, Russo S, Facoetti A, Vai A, Mastella E, Viselner G, Raciti M, Fanizza M, Magro G, Maestri D, Ciocca M, Preda L, Valvo F, Orecchia R. P05.39 Skull-base chordoma treated with proton and carbon ion radiotherapy: C.N.A.O. clinical experience. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
83
|
Savini A, Fusella M, Esposito M, Carbonini C, Clemente S, Fiandra C, Garibaldi C, Giglioli F, Marino C, Moretti E, Russo S, Strigari L, Villaggi E, Stasi M, Mancosu P. [P187] A crowd-knowledge-based analysis of DVHs in SBRT: First steps towards a national virtual audit. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.06.487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
84
|
Russo S, Alves V, Raposo S, Lérias C, Matos P. 254 Vaginal stenosis prevention program: The evidence of practice. J Sex Med 2018. [DOI: 10.1016/j.jsxm.2018.04.219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
85
|
De Sanctis A, Russo S, Craciun MF, Alexeev A, Barnes MD, Nagareddy VK, Wright CD. New routes to the functionalization patterning and manufacture of graphene-based materials for biomedical applications. Interface Focus 2018; 8:20170057. [PMID: 29696089 DOI: 10.1098/rsfs.2017.0057] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/31/2018] [Indexed: 12/17/2022] Open
Abstract
Graphene-based materials are being widely explored for a range of biomedical applications, from targeted drug delivery to biosensing, bioimaging and use for antibacterial treatments, to name but a few. In many such applications, it is not graphene itself that is used as the active agent, but one of its chemically functionalized forms. The type of chemical species used for functionalization will play a key role in determining the utility of any graphene-based device in any particular biomedical application, because this determines to a large part its physical, chemical, electrical and optical interactions. However, other factors will also be important in determining the eventual uptake of graphene-based biomedical technologies, in particular the ease and cost of manufacture of proposed device and system designs. In this work, we describe three novel routes for the chemical functionalization of graphene using oxygen, iron chloride and fluorine. We also introduce novel in situ methods for controlling and patterning such functionalization on the micro- and nanoscales. Our approaches are readily transferable to large-scale manufacturing, potentially paving the way for the eventual cost-effective production of functionalized graphene-based materials, devices and systems for a range of important biomedical applications.
Collapse
|
86
|
Donofrio V, Passeretti U, Russo S, Boscaino A, De Rosa G. Neurothekeoma of the Thumb. A Case Report. TUMORI JOURNAL 2018; 74:751-4. [PMID: 3232219 DOI: 10.1177/030089168807400622] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A benign tumor of nerve sheath origin occurring in the dermis of a thumb is described. Histologically, these lesions contained nests and cords of large cells surrounded by thin bands of collagen fibers scattered in a myxoid background. The immunocytochemical reaction for S-100 protein was positive.
Collapse
|
87
|
Russo S, Rossi F, Esposito M, Pini S, Barca R, Fondelli S, Paoletti L, Bastiani P. EP-1983: Robust DIBH 3D conformal irradiation technique of left sided whole breast + supraclavicular region. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32292-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
88
|
Villaggi E, Esposito M, Marino C, Hernandez V, Saez J, Bruschi A, Borzì G, Carbonini C, Consorti R, Fedele D, Moretti E, Nardiello B, Russo S, Stasi M, Mancosu P. PO-1012: Can re-planning improve standardization? A multi-institutional SBRT prostate comparison. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31322-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
89
|
Falco M, Clemente S, Cagni E, Landoni V, Russo S, Talamonti C, Alparone A, Vinciguerra A, Fiandra C. EP-1946: Effect of small field (SF) output factor (OF) measurements on FSBRT VMAT plans. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32255-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
90
|
Esposito M, Ghirelli A, Pini S, Russo S, Zatelli G, Alpi P, Barca R, Coppola M, Fondelli S, Grilli Leonulli B, Paoletti L, Rossi F, Bastiani P. EP-1780: Volumetric EPID transit dosimetry for abdominal and pelvic stereotactic treatments. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32089-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
91
|
Marino C, Carbonini C, Veronese I, Clemente S, Esposito M, Fiandra C, Fusella M, Garibaldi C, Giglioli F, Moretti E, Russo S, Savini A, Strigari L, Strolin S, Talamonti C, Villaggi E, Stasi M, Mancosu P. EP-2191: Design of a national survey to assess the technology applied to SBRT. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32500-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
92
|
Zani M, Esposito M, Carbonini C, Clemente S, Fiandra C, Fusella M, Garibaldi C, Giglioli F, Marino C, Moretti E, Russo S, Savini A, Strigari L, Strolin S, Talamonti C, Villaggi E, Stasi M, Mancosu P. EP-1980: Influence of different DVH algorithms on dose constraints evaluation for SBRT. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32289-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
93
|
Russo P, Papa V, Russo S, Bella AD, Pabst G, Milazzo G, Balestrazzi A, Caporossi A, Anselmetti G, Lorenzi U, Orsi R, Faletti P, Bindella G, Boccassini G, Kropp B, Calabria G, Campagna P, Ciurlo C, Caporossi A, Tasciotti A, Licignano R, Balestrazzi A, Caprioglio G, Birattari F, Franch A, Darondeau J, Blanluet G, Ouen S, Guerra R, Saccarola P, Lenz W, Schuff O, Lùpidi G, Coiràn M, Checcucci M, Burattini L, Foligno, Mastropasqua L, Ciancaglini M, Ciafrè M, Cerulli A, Moretti G, Padovano S, Rotondo SG, Neuhann T, Okrafka K, Ratiglia R, Oldani A, Reiss H, Rochefort J, Coulombe B, Sborgia C, Lorusso V, Palmisano C, Moramarco N, Spinelli D, Curatola M, Maruccia A, Vaona P, Faraldi F, Villani C, Schiavone M, Gisoldi RC. Topical Nonsteroidal Anti-Inflammatory Drugs in Uncomplicated Cataract Surgery: Effect of Sodium Naproxen. Eur J Ophthalmol 2018. [DOI: 10.1177/112067210501500510] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose To investigate whether topical nonsteroidal anti inflammatory drugs (NSAIDs) are useful, in the absence of concomitant corticosteroid therapy, in limiting postoperative inflammation after uncomplicated cataract surgery. Methods A total of 328 patients were enrolled in a prospective, randomized, double-masked, parallel-group, active-controlled study. Anterior chamber inflammation (ACI) was evaluated as the primary efficacy parameter. Only patients with moderate inflammation (ACI score of ≤4) the day after surgery were randomized and treated with NSAIDs. A novel topical formulation containing 0.2% sodium naproxen was compared with 0.1% diclofenac. Both were administered three times a day for 14 consecutive days. Ocular inflammation was measured after 7 and 14 days by using slit-lamp biomicroscopy. Safety parameters were also evaluated at the same time. Results Both treatments were equally effective in controlling postsurgical inflammation. No statistically significant differences between treatment groups were observed for the safety variables. No serious adverse events (AEs) occurred during the course of the study. The most frequent AE reported with naproxen was eye redness. Conclusions NSAIDs can effectively be used without concurrent administration of corticosteroids to control postoperative inflammation after uncomplicated cataract surgery. In addition, naproxen ophthalmic solution may be considered a suitable alternative to the currently available NSAIDs.
Collapse
|
94
|
Bruschi A, Esposito M, Pini S, Ghirelli A, Zatelli G, Russo S. How the detector resolution affects the clinical significance of SBRT pre-treatment quality assurance results. Phys Med 2017; 49:129-134. [PMID: 29203119 DOI: 10.1016/j.ejmp.2017.11.012] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 09/22/2017] [Accepted: 11/15/2017] [Indexed: 10/18/2022] Open
Abstract
PURPOSE Aim of this work was to study how the detector resolution can affect the clinical significance of SBRT pre-treatment volumetric modulated arc therapy (VMAT) verification results. METHODS Three detectors (PTW OCTAVIUS 4D 729, 1500 and 100 SRS) used in five configurations with different resolution were compared: 729, 729 merged, 1500, 1500 merged and 1000 SRS. Absolute local gamma passing rates of 3D pre-treatment quality assurance (QA) were evaluated for 150 dose distributions in 30 plans. Five different kinds of error were introduced in order to establish the detection sensitivity of the three devices. Percentage dosimetric differences were evaluated between planned dosevolume histogram (DVH) and patients' predicted DVH calculated by PTW DVH 4D® software. RESULTS The mean gamma passing rates and the standard deviations were 92.4% ± 3.7%, 94.6% ± 1.8%, 95.3% ± 4.2%, 97.4% ± 2.5% and 97.6% ± 1.4 respectively for 729, 729 merged, 1500, 1500 merged and 1000 SRS with 2% local dose/2mm criterion. The same trend was found on the sensitivity analysis: using a tight gamma analysis criterion (2%L/1mm) only the 1000 SRS detected every kind of error, while 729 and 1500 merged detected three and four kinds of error respectively. Regarding dose metrics extracted from DVH curves, D50% was within the tolerance level in more than 90% of cases only for the 1000 SRS. CONCLUSIONS The detector resolution can significantly affect the clinical significance of SBRT pre-treatment verification results. The choice of a detector with resolution suitable to the investigated field size is of main importance to avoid getting false positive.
Collapse
|
95
|
Mastella E, Molinelli S, Magro G, Mirandola A, Russo S, Vai A, Mairani A, Choi K, Fiore M, Fossati P, Cuzzocrea F, Gasbarrini A, Benazzo F, Boriani S, Valvo F, Orecchia R, Ciocca M. Dosimetric characterization of carbon fiber stabilization devices for post-operative particle therapy. Phys Med 2017; 44:18-25. [DOI: 10.1016/j.ejmp.2017.11.008] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2017] [Revised: 09/05/2017] [Accepted: 11/09/2017] [Indexed: 11/15/2022] Open
|
96
|
Bonotto M, Basile D, Gerratana L, Pelizzari G, Bartoletti M, Vitale M, Fanotto V, Lisanti C, Bozza C, Cinausero M, Andreetta C, Russo S, Mansutti M, Minisini A, Merlini L, De Laurentiis M, Montemurro F, Fasola G, Del Mastro L, Puglisi F. Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
97
|
Vitale M, Bonotto M, Gerratana L, Basile D, Bartoletti M, Pelizzari G, Fanotto V, Lisanti C, Bozza C, Cinausero M, Iacono D, Poletto E, Barban S, Mansutti I, Minisini A, Russo S, Andreetta C, Mansutti M, Fasola G, Puglisi F. Strategy of monitoring metastatic breast cancer (M-MBC) in clinical practice: more or less intensive? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
98
|
Bozza C, Gerratana L, Basile D, De Carlo E, Cortiula F, Pella N, Vitale M, Bartoletti M, Russo S, Bonotto M, Cinausero M, Fanotto V, Pelizzari G, Minisini A, Andreetta C, Mansutti M, Iacono D, Sottile R, Fasola G, Puglisi F. Final results from CAMEO-PRO study: complementary and alternative medicine in oncology. physicians inform oncological patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx436.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
99
|
Cazzaniga M, Cagossi K, Valerio M, Russo S, Casadei V, Scognamiglio G, Cavanna L, Toniolo D, De Conciliis E, Melegari E, Stocchi L, Gebbia V, Vandone A, Cursano M, Pinotti G, Rossello R, Ortu S, Pellegrino B, Saracchini S, Torri V. Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Old drugs, new opportunities Preliminary results of the VICTOR-6 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
100
|
Russo S, Mccaffery K, Ellard J, Poynten M, Prestage G, Templeton DJ, Hillman R, Law C, Grulich AE. Experience and psychological impact of anal cancer screening in gay, bisexual and other men who have sex with men: a qualitative study. Psychooncology 2017. [PMID: 28635044 DOI: 10.1002/pon.4480] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVE Human papillomavirus-related anal cancer rates are increasing and are particularly high in gay, bisexual and other men who have sex with men (GBM/MSM), especially HIV-positive individuals. Although screening programs for high-risk populations have been advocated, concerns about possible adverse psychological consequences exist. This study aimed to investigate GBM/MSM's experience, understanding and emotional response to screening techniques for anal cancer to determine how best to minimise psychological distress in future programs. METHODS In-depth qualitative face-to-face interviews were conducted with 21 GBM/MSM participating in the "Study of the Prevention of Anal Cancer" in Sydney, Australia, between June 2013 and June 2014. Nonrandom, purposive sampling was used to ensure heterogeneity with respect to HIV status and screening test results. Framework analysis method was used to organise the data and identify emerging themes. RESULTS Knowledge about anal cancer, human papillomavirus and the link between them was limited. Abnormal screening results affected participants' sense of well-being and were associated with anxiety and concern about developing anal cancer. HIV-negative men receiving abnormal results showed higher levels of distress compared to their HIV-positive counterparts. Consultations with general practitioners about abnormal results had an important role in increasing participants' understanding and in moderating their anxiety. CONCLUSION Anal cancer screening should be accompanied by health education around anal cancer, its aetiology and the meaning of associated test results. Simple and effective communication strategies should be encouraged. Collaboration with general practitioners could assist the process of education and reporting test results.
Collapse
|